Allogeneic bone marrow transplantation (aBMT; i.e., a bone marrow transplantation whereby the donor is not genetically related to the recipient) is still the only potential cure for MDS patients. However, an aBMT may cause serious complications, some of which may result in death. In other cases, MDS will come back. The aim of this study was to identify patient characteristics that would predict survival in MDS patients after an aBMT.
A retrospective study (i.e., a study in which patient’s disease characteristics and history are investigated going back in time) showed that of the many parameters tested, the following were associated with inferior survival: chromosomal abnormalities that would classify as high risk in the “Revised International Prognostic Scoring” systems, poor to very poor scores in that same scoring system, therapy-related MDS (i.e., MDS that is associated with prior anti-cancer treatments) and the presence of a monosomal karyotype-a certain type of chromosomal abnormality - normally, every human cell contains 22 pairs of non-sex chromosomes and one pair of sex chromosomes (the X and Y chromosomes) but in a monosomal karyotype there are at least two non-sex chromosomal pairs that have lost one member of the pair, or there is one chromosome that consists of only one copy but is combined with structural changes in another chromosome.) Associated with superior survival was the presence of chronic Graft versus Host Disease, a chronic condition whereby donor cells elicit a certain immune response against the cells of the host.
Research presented at the European Hematology Assocation annual meeting on treatment of therapy-related MDS and prediction of outcomes after stem cell transplantation for MDS